 III. To determine whether mRNA expression levels of genes involved in the gemcitabine pathway RR, dck, dcd and genes involved in the Raf pathway cyclin D, VEGFR2, p21 will predict for time to progression, overall survival, and response, in patients with metastatic pancreatic cancer treated with concurrent gemcitabine and BAY43-9006 and sequential BAY 43-9006 followed by gemcitabineBAY 43-9006 at progression. 